 The FDA has signed off Phase 1b2 trial for Moleculin Biotech Incs NASDAQ: MBRX Annamycin to treat soft tissue sarcoma lung metastases. Annamycin is the companys next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. 